COLLAGEN CROSS-LINKING WITH ULTRAVIOLET-A IN ASYMMETRIC CORNEAS
Status: | Recruiting |
---|---|
Conditions: | Ocular, Ocular, Dermatology, Dermatology |
Therapuetic Areas: | Dermatology / Plastic Surgery, Ophthalmology |
Healthy: | No |
Age Range: | 8 - Any |
Updated: | 10/14/2018 |
Start Date: | December 21, 2016 |
End Date: | January 1, 2020 |
Contact: | Debi S Gravemann, RN |
Email: | dg@cxlusa.com |
Phone: | (314) 966-3377 |
This study will assess changes in visual acuity and corneal symmetry after corneal collagen
cross-linking (CXL) of asymmetric corneas.
cross-linking (CXL) of asymmetric corneas.
This study will evaluate the results of Corneal Collagen Crosslinking (CXL) in patients with
conditions that include keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid
marginal degeneration, forme fruste pellucid marginal degeneration, diurnal fluctuation
post-radial keratotomy, or Terrien's marginal degeneration. This is an outcomes study, all
patients receive treatment.
conditions that include keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid
marginal degeneration, forme fruste pellucid marginal degeneration, diurnal fluctuation
post-radial keratotomy, or Terrien's marginal degeneration. This is an outcomes study, all
patients receive treatment.
Inclusion Criteria:
- A diagnosis of at least one of the following conditions:
1. Keratoconus
2. Forme fruste keratoconus
3. Post-LASIK ectasia
4. Pellucid marginal degeneration
5. Forme fruste pellucid marginal degeneration
6. Diurnal fluctuation post-radial keratotomy
7. Terrien's marginal degeneration
Exclusion Criteria:
1. Corneal thickness < 375 microns measured by ultrasound or Pentacam.
2. Contraindications or hypersensitivities to any study medications or their components.
3. Pregnancy or breastfeeding.
4. Any history of herpes simplex corneal disease in an eye to be treated.
5. Nystagmus or any other condition that would, in the judgement of the investigator,
prevent a steady gaze during the treatment.
6. Inability to cooperate with diagnostic tests.
7. Enrollment in another ophthalmic clinical trial.
We found this trial at
9
sites
Dallas, Texas 75231
Principal Investigator: Brad Bowman, MD
Phone: 214-692-0146
Click here to add this to my saved trials
Atlanta, Georgia 30328
Principal Investigator: Doyle Stulting, MD, PhD
Phone: 770-740-0233
Click here to add this to my saved trials
Brecksville, Ohio 44141
Principal Investigator: Shamik Bafna, MD
Phone: 216-503-6535
Click here to add this to my saved trials
Chicago, Illinois 60035
Principal Investigator: Randy Epstein, MD
Phone: 847-432-6010
Click here to add this to my saved trials
Hoffman Estates, Illinois
Principal Investigator: Parag A Majmudar, MD
Phone: 847-432-6010
Click here to add this to my saved trials
Littleton, Colorado 80120
Principal Investigator: S. Lance Forstot, MD
Phone: 720-709-7533
Click here to add this to my saved trials
Saint Louis, Missouri 63131
Principal Investigator: Gregg J Berdy, MD
Phone: 314-966-5000
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Dan Goodman, MD
Phone: 415-474-3333
Click here to add this to my saved trials
8416 E. Shea Blvd., Ste C-101
Scottsdale, Arizona 85260
Scottsdale, Arizona 85260
Phone: 480-483-3937
Click here to add this to my saved trials